Excelsior Sciences

Excelsior Sciences of New York is a biotechnology company focused on transforming small molecule therapeutic drug discovery. The company utilizes a modular chemistry approach, leveraging 'smart blocks' as the foundational elements for drug design and synthesis. This methodology enables automated chemistry, which, when coupled with automated testing, significantly reduces the design-make-test-analyze cycle to as little as two weeks.

The firm's process is designed to rapidly generate high-quality data, which is then used to leverage artificial intelligence and machine learning (AI/ML) for multiparameter optimization, creating closed learning loops to develop better medicines quickly. This automated approach also allows for the onshoring of integrated drug discovery, with all operations based in the U.S. Excelsior Sciences operates the "Lab of the Future" in New York City, a project supported by a $25 million grant from Empire State Development (ESD) and developed in partnership with Deerfield Management Company. This automated research facility is designed to set a new standard for early-stage life sciences research.

The company is led by CEO Michael Foley, PhD. The lab aims to serve businesses within New York, offering efficiency, quality, and intellectual property protection, thereby bolstering the state's life science ecosystem. The business model centers on providing accelerated drug lead discovery services and leveraging its advanced technology platform for partnerships within the pharmaceutical and biotech industries.

Keywords: small molecule drug discovery, modular chemistry, automated synthesis, AI in drug discovery, machine learning in pharma, preclinical research, therapeutic drug discovery, drug design, life sciences, automated testing, high-throughput screening, lead optimization, multiparameter optimization, smart blocks, drug development, biotechnology, pharmaceutical research, integrated drug discovery, Lab of the Future, preclinical development